Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine + gemcitabine dose-finding and activity study in metastatic breast cancer
2005-001271-35Phase 2Active
- Sponsor
- Azienda USL Toscana Nord Ovest
- Start
- Jan 2006
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and gemcitabine in breast cancer, sponsored by Azienda USL Toscana Nord Ovest. Primary endpoints: Objective response and Maximum tolerated dose of gemcitabine in combination. Started Jan 2006; status: active.
02
Drugs
capecitabinegemcitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-001271-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001271-35.